-
Mashup Score: 0Bleeding risk, protective effects of aspirin for primary CVD prevention must be weighed - 4 year(s) ago
The current literature does not support the use of aspirin for primary prevention in patients with diabetes, and physicians must balance the benefits of prevention with the increased risk for major bleeding, according to a speaker.At the virtual Heart in Diabetes Conference, Richard C. Becker, MD, FAHA, professor of medicine and director of the Heart, Lung and Vascular Institute at the University
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Cardiologists and clinicians do not often recognize the sex-specific CVD pathophysiology in women, especially when using imaging modalities to diagnose patients, according to a speaker.Coronary CTA may provide a benefit in women compared with functional imaging for diagnosis and for treatment planning, Matthew J. Budoff, MD, FACC, professor of medicine in the division of cardiology at Harbor-UCLA
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: Coronary CTA may provide a benefit in women compared with functional imaging for diagnosis and for treatment planning, @heartindiabetes #HID2020 #cardiotwitter @BudoffMd https://t.co/8WkbOgEryP
-
-
Mashup Score: 0Bleeding risk, protective effects of aspirin for primary CVD prevention must be weighed - 4 year(s) ago
The current literature does not support the use of aspirin for primary prevention in patients with diabetes, and physicians must balance the benefits of prevention with the increased risk for major bleeding, according to a speaker.At the virtual Heart in Diabetes Conference, Richard C. Becker, MD, FAHA, professor of medicine and director of the Heart, Lung and Vascular Institute at the University
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: “We have to find the happy medium. We have to find the balance and decide who is at greatest likelihood of benefit while minimizing risk," Richard C. Becker, MD, FAHA @UCHealthNews @heartindiabetes #HID2020 @EndocrineToday https://t.co/K9RoNrzZlI
-
-
Mashup Score: 1
Cardiologists and clinicians do not often recognize the sex-specific CVD pathophysiology in women, especially when using imaging modalities to diagnose patients, according to a speaker.Coronary CTA may provide a benefit in women compared with functional imaging for diagnosis and for treatment planning, Matthew J. Budoff, MD, FACC, professor of medicine in the division of cardiology at Harbor-UCLA
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Cardiologists and clinicians do not often recognize the sex-specific CVD pathophysiology in women, especially when using imaging modalities to diagnose patients @heartindiabetes #HID2020 #cardiotwitter @BudoffMd https://t.co/8WkbOgW2Xp
-
-
Mashup Score: 0
Triple therapy combining an SGLT2 inhibitor, a GLP-1 receptor agonist and the thiazolidinedione pioglitazone could serve as an optimal solution for cardiovascular and renal protection in type 2 diabetes, according to a speaker.The impact of triple therapy on CV outcomes remains difficult to discern; there are no randomized controlled trial data on combination therapy assessing outcomes, Ralph A.
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: “To me, if we are going to talk about combination therapy, we need to look at those antidiabetic medications that have documented cardiovascular benefit." @heartindiabetes #HID2020 https://t.co/f0kjVsELE2
-
-
Mashup Score: 3Bleeding risk, protective effects of aspirin for primary CVD prevention must be weighed - 4 year(s) ago
The current literature does not support the use of aspirin for primary prevention in patients with diabetes, and physicians must balance the benefits of prevention with the increased risk for major bleeding, according to a speaker.At the virtual Heart in Diabetes Conference, Richard C. Becker, MD, FAHA, professor of medicine and director of the Heart, Lung and Vascular Institute at the University
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
The current literature does not support the use of aspirin for primary prevention in patients with diabetes, and physicians must balance benefits of prevention with increased risk for major bleeding @UCHealthNews @heartindiabetes #HID2020 @EndocrineToday https://t.co/K9RoNrRAKi
-
-
Mashup Score: 3
Triple therapy combining an SGLT2 inhibitor, a GLP-1 receptor agonist and the thiazolidinedione pioglitazone could serve as an optimal solution for cardiovascular and renal protection in type 2 diabetes, according to a speaker.The impact of triple therapy on CV outcomes remains difficult to discern; there are no randomized controlled trial data on combination therapy assessing outcomes, Ralph A.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Individualized therapy is needed for cardiovascular protection in the setting of type 2 #diabetes. @heartindiabetes #HID2020 https://t.co/7F9391Rvbn
-
Individualized therapy is needed for cardiovascular protection in the setting of type 2 #diabetes. @heartindiabetes #HID2020 https://t.co/z28LWjC3gw
-
Individualized therapy is needed for cardiovascular protection in the setting of type 2 #diabetes. @heartindiabetes #HID2020 https://t.co/ubAZEEjCzi
-
-
Mashup Score: 0
Two paradigm shifts have established SGLT2 inhibitors as an important drug class to treat cardiac dysfunction and HF with reduced ejection fraction in patients with and without diabetes, according to a presentation.The first discussion of SGLT2 inhibitors was in a paper published in Diabetes in 1999, in which a novel agent was introduced to lower blood glucose in patients with diabetes, Eugene
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: "What we can say now about SGLT2 inhibition [is that] it shows efficacy in the prevention of heart failure in patients with type 2 diabetes” @heartindiabetes #HID2020 #cardiotwitter @BrighamWomens @EndocrineToday https://t.co/JVawVsTrRT
-
-
Mashup Score: 0
Two paradigm shifts have established SGLT2 inhibitors as an important drug class to treat cardiac dysfunction and HF with reduced ejection fraction in patients with and without diabetes, according to a presentation.The first discussion of SGLT2 inhibitors was in a paper published in Diabetes in 1999, in which a novel agent was introduced to lower blood glucose in patients with diabetes, Eugene
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: "What we can say now about SGLT2 inhibition [is that] it shows efficacy in the prevention of heart failure in patients with type 2 diabetes” @heartindiabetes #HID2020 #cardiotwitter @BrighamWomens @EndocrineToday https://t.co/JVawVsTrRT
-
-
Mashup Score: 7
Two paradigm shifts have established SGLT2 inhibitors as an important drug class to treat cardiac dysfunction and HF with reduced ejection fraction in patients with and without diabetes, according to a presentation.The first discussion of SGLT2 inhibitors was in a paper published in Diabetes in 1999, in which a novel agent was introduced to lower blood glucose in patients with diabetes, Eugene
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Two paradigm shifts established SGLT2 inhibitors as an important drug class to treat cardiac dysfunction and HF with reduced ejection fraction in patients with and without diabetes @heartindiabetes #HID2020 #cardiotwitter @BrighamWomens @EndocrineToday https://t.co/JVawVtb2Jr
-
ICYMI: “We have to find the happy medium. We have to find the balance and decide who is at greatest likelihood of benefit while minimizing risk," Richard C. Becker, MD, FAHA @UCHealthNews @heartindiabetes #HID2020 @EndocrineToday https://t.co/K9RoNrRAKi